Company Profile

Zhejiang Jingxin Pharmaceutical Co., Ltd.
Year Established : 1974
Total Assets(USD) : choose not to disclose
Total Number of Staff : more than 500
  • Contact Person :
  • Fax:

Jingxin Pharm was established in 1974 and has been developed as one of the National Important High-tech Enterprises, Top 100 Pharmaceutical Enterprises and the Listed Company. The headquarter is located at Xinchang City, Zhejiang Province. It is an integrated company covers manufacturing, R & D and marketing center. There are 4 manufacturing sites in the company located at Xinchang, Shangyu, Shangrao Guangfeng (Jiangxi province) and Bayannaoer (Inner Mongolia) respectively. There is R & D center in Shanghai High-tech Park and a marketing center in Hangzhou city. It has been appointed as the Post-doctoral Working Station and the Technical Center of the province and has the close cooperation relationship with some of the national research authorities. It has a strong R & D ability.
The products covered from API to Finished Product, more than 160 products have been approved. It is one the biggest manufacturing base for the APIs of quinolones and occupied a relatively large market share for the product named Ciprofloxacin Hydrochloride and the Levofloxacin Hydrochloride. The product has been distributed to the international market such as South-east of Asia, South Asia, Latin America and Europe. The dosage forms of the formulation include Tablets, Capsules, Large volume Injections and Powder for Injections. The sales volume of products named Simvastatin and Rosuvastatin Calcium Tablets rank the first in the domestic market as compared with the domestic manufacturers.
All of its facilities have been approved by sFDA and ISO14001. In the year 2006, it has been approved by EU (Germany) GMP inspection and in Oct. 2009 passed the related re-inspection successfully; this is the first case for the company which has been approved by the Germany GMP in China. In the year 2008, Simvastatin Tablets distributed to UK and gave the first step for the Chinese formulation exporting to the high-end market. In the year 2009, the product has been distributed into Germany market. The quality of the products can meet the EU requirement.
 

PharmaSources Customer Service